Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis

Figure 4 Progression-free survival comparison between regorafenib and control treatments and sensitivity analysis of the pooled estimate. A: Forest plot of progression-free survival (PFS) comparing regorafenib vs control therapies. A random-effects model was applied due to substantial heterogeneity (I² = 95.5%). No statistically significant difference in PFS was observed between groups (weighted mean difference = 1.04; 95% confidence interval: -1.27 to 3.36; P > 0.05); B: Sensitivity analysis of pooled PFS results by sequential study exclusion. The results remained stable across iterations, confirming that no individual study had a major impact on the overall pooled effect. CI: Confidence interval.